Small Cell Cancer of the Lung disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

SCCL MCID: SML038 MIFTS: 68	Small Cell Cancer of the Lung (SCCL) Categories: Cancer diseases, Rare diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Small Cell Cancer of the Lung

MalaCards integrated aliases for Small Cell Cancer of the Lung:

Name: Small Cell Cancer of the Lung ⁵⁷

Small Cell Lung Carcinoma ²⁸ ⁵ ⁴³ ¹⁶

Small Cell Lung Cancer ¹⁹ ⁵⁸ ⁷⁵ ⁵³

Small-Cell Cancer of Lung ⁵⁷ ¹²

Lung Small Cell Carcinoma ¹¹ ¹⁴

Sclc ⁵⁷ ⁵⁸

Small Cell Carcinoma of Lung ⁷¹

Cancer, Lung, Small Cell ³⁸

Carcinoma, Small Cell ⁷¹

Sclc1 ⁵⁷

Sccl ⁵⁷

Characteristics:

Inheritance:

Autosomal dominant ⁵⁷

Prevelance:

Small Cell Lung Cancer: 1-5/10000 (Europe) ⁵⁸

Age Of Onset:

Small Cell Lung Cancer: Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of respiratory and intrathoracic organs

Malignant neoplasm of bronchus and lung

Malignant neoplasm: Bronchus or lung, unspecified

Orphanet: ⁵⁸

Rare respiratory diseases

External Ids:

Disease Ontology ¹¹ DOID:5409

OMIM® ⁵⁷ 182280

MeSH ⁴³ D055752

NCIt ⁴⁹ C4917

SNOMED-CT ⁶⁸ 254632001

ICD10 via Orphanet ³² C34.9

UMLS via Orphanet ⁷² C0149925

Orphanet ⁵⁸ ORPHA70573

MedGen ⁴⁰ C0149925

SNOMED-CT via HPO ⁶⁹ 126713003

EFO ¹⁶ EFO_0000702

UMLS ⁷¹ C0149925 C0262584

Sources

Summaries for Small Cell Cancer of the Lung

Orphanet: ⁵⁸ Small cell lung cancer (SCLC) is a highly aggressive malignant neoplasm, accounting for 10-15% of lung cancer cases, characterized by rapid growth, and early metastasis. SCLC usually manifests as a large hilar mass with bulky mediastinal lymphadenopathy presenting clinically with chest pain, persistent cough, dyspnea, wheezing, hoarseness, hemoptysis, loss of appetite, weight loss, and neurological and endocrine paraneoplastic syndromes. SCLC is primarily reported in elderly people with a history of long-term tobacco exposure.

MalaCards based summary: Small Cell Cancer of the Lung, also known as small cell lung carcinoma, is related to lung squamous cell carcinoma and melanoma. An important gene associated with Small Cell Cancer of the Lung is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Endometrial cancer and Hepatocyte growth factor receptor signaling. The drugs Erlotinib and Vinblastine have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and brain, and related phenotypes are neoplasm of the lung and neoplasm

Disease Ontology: ¹¹ A lung carcinoma that has material basis in primitive-appearing cells that are smaller than normal cells and is located in the lung.

Wikipedia: ⁷⁵ Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung,... more...

More information from OMIM: 182280

Sources

Related Diseases for Small Cell Cancer of the Lung

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung

Lung Clear Cell Carcinoma

Diseases related to Small Cell Cancer of the Lung via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1704)

#	Related Disease	Score	Top Affiliating Genes
1	lung squamous cell carcinoma	32.2	TUG1 TP53 RB1 PTEN PIK3CA CCAT2
2	melanoma	31.6	TP53 RB1 PTEN PIK3CA MIR21 MALAT1
3	head and neck cancer	31.5	TP53 PTEN PIK3CA MIR21 AKT1
4	esophagus squamous cell carcinoma	31.5	TUG1 MALAT1 HOTTIP HOTAIR
5	mucinous adenocarcinoma	31.5	TP53 PIK3CA NKX2-1
6	polyploidy	31.5	TP73 TP53
7	lung large cell carcinoma	31.4	TP53 SYP NKX2-1 NCAM1 GRP ENO2
8	spinal cord disease	31.4	TP53 SYP PTEN AKT1
9	appendix adenocarcinoma	31.4	TP53 SYP CHGA
10	esophageal cancer	31.4	TP73 TP53 RB1 PTEN PIK3CA MIR21
11	osteogenic sarcoma	31.4	TUG1 TP53 RB1 MALAT1 HOTTIP HOTAIR
12	kidney cancer	31.4	TP53 PIK3CA MIR21 MALAT1 HOTAIR
13	sarcoma	31.3	TP53 RB1 PIK3CA HOTAIR ENO2
14	stroke, ischemic	31.3	PIK3CA MIR21 MALAT1 ENO2 AKT1
15	papillary adenocarcinoma	31.2	TP53 NKX2-1 MIR21
16	squamous cell carcinoma, head and neck	31.2	TP73 TP53 RB1 PTEN PIK3CA MIR21
17	retinitis pigmentosa 11	31.2	TUG1 TP53 PTEN HOTAIR CCAT2 AKT1
18	lung cancer	31.2	TUG1 TP73 TP53 SYP RB1 PTEN
19	lip and oral cavity cancer	31.2	TP53 RB1 PIK3CA MIR21
20	leukemia, acute myeloid	31.1	TUG1 TP53 PTEN PIK3CA NCAM1 MIR21
21	ovarian cancer	31.1	TUG1 TP73 TP53 RB1 PTEN PIK3CA
22	leukemia, chronic lymphocytic	31.1	TP53 PTEN NCAM1 MIR21 B2M AKT1
23	colonic benign neoplasm	31.1	TP53 PTEN PIK3CA MIR21 AKT1
24	lymphoepithelioma-like carcinoma	31.1	TP53 SYP NCAM1 ENO2
25	neurofibromatosis, type i	31.1	TP53 PTEN ENO2 AKT1
26	renal cell carcinoma, nonpapillary	31.1	TUG1 TP53 PTEN PIK3CA NKX2-1 MIR21
27	pancreatic ductal adenocarcinoma	31.1	TP53 MIR21 MALAT1 HOTTIP HOTAIR
28	glioblastoma	31.0	TUG1 TP53 RB1 PTEN PIK3CA MIR21
29	bladder cancer	31.0	TUG1 TP73 TP53 RB1 PTEN PIK3CA
30	nasopharyngeal carcinoma	31.0	TP53 PTEN PIK3CA MIR21 MALAT1 HOTAIR
31	skin carcinoma	31.0	TP53 SYP PTEN MIR21 AKT1
32	mediastinal cancer	31.0	SYP NKX2-1 NCAM1 ENO2 CHGA
33	glioma	31.0	TP53 PTEN PIK3CA MIR21 MALAT1 HOTTIP
34	mixed cell type cancer	31.0	TP53 SYP PTEN PIK3CA ENO2 CHGA
35	thyroid carcinoma, familial medullary	31.0	NKX2-1 MALAT1 GRP CHGA
36	lynch syndrome	31.0	TP53 PTEN PIK3CA AKT1
37	small cell carcinoma	31.0	TP53 SYP PTEN NKX2-1 NCAM1 GRP
38	acute promyelocytic leukemia	31.0	TP73 TP53 PTEN PIK3CA NCAM1 AKT1
39	carcinosarcoma	31.0	TP53 SYP PTEN PIK3CA
40	ovarian epithelial cancer	31.0	MALAT1 HOTAIR CCAT2
41	skin squamous cell carcinoma	30.9	TP53 PTEN MIR21 HOTAIR AKT1
42	thyroid gland medullary carcinoma	30.9	SYP NKX2-1 CHGA
43	adenoid cystic carcinoma	30.9	TP53 PTEN PIK3CA NCAM1 AKT1
44	lung oat cell carcinoma	30.9	TP53 SYP RB1 PTEN PIK3CA ENO2
45	bladder small cell carcinoma	30.9	SYP NCAM1 ENO2
46	papilloma	30.9	TP53 RB1 PTEN AKT1
47	hepatocellular carcinoma	30.9	TUG1 TP73 TP53 RB1 PTEN PIK3CA
48	pulmonary large cell neuroendocrine carcinoma	30.9	SYP NKX2-1 NCAM1 ENO2 CHGA
49	hydrocephalus	30.9	TP53 SYP PTEN NCAM1 ENO2
50	merkel cell carcinoma	30.9	SYP NKX2-1 NCAM1 ENO2 CHGA

Graphical network of the top 20 diseases related to Small Cell Cancer of the Lung:

Sources

Symptoms & Phenotypes for Small Cell Cancer of the Lung

Human phenotypes related to Small Cell Cancer of the Lung:

³⁰

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	neoplasm of the lung ³⁰			HP:0100526

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Oncology:
small-cell lung cancer

Lab:
3p23-p14 chromosome deletion in tumor

Misc:
sensitive to chemotherapy and radiotherapy

Clinical features from OMIM®:

182280 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Small Cell Cancer of the Lung:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.92	AKT1 B2M NKX2-1 PIK3CA PTEN RB1
2	normal	MP:0002873	9.91	AKT1 HOTTIP MALAT1 NKX2-1 PTEN RB1
3	no phenotypic analysis	MP:0003012	9.81	CHGA HOTAIR HOTTIP MALAT1 NKX2-1 PIK3CA
4	nervous system	MP:0003631	9.8	AKT1 B2M CHGA ENO2 GRP MALAT1
5	respiratory system	MP:0005388	9.23	AKT1 ENO2 GRP NKX2-1 PTEN RB1

Sources

Drugs & Therapeutics for Small Cell Cancer of the Lung

Drugs for Small Cell Cancer of the Lung (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 763)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Erlotinib

Approved, Investigational

Phase 4

183319-69-9, 183321-74-6

176870

Vinblastine

Approved

Phase 4

865-21-4

241903 13342

Sunitinib

Approved, Investigational

Phase 4

557795-19-4

5329102

Caffeine

Approved

Phase 4

58-08-2

2519

Dabrafenib

Approved, Investigational

Phase 4

1195765-45-7

44462760

Ondansetron

Approved, Withdrawn

Phase 4

99614-02-5

4595

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Midazolam

Approved, Illicit

Phase 4

59467-70-8

4192

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Cisatracurium

Approved, Investigational

Phase 4

96946-41-7

62887

Ropivacaine

Approved

Phase 4

84057-95-4

71273 175805

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Magnesium sulfate

Approved, Investigational, Vet_approved

Phase 4

7487-88-9

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 4

86347-14-0, 113775-47-6

68602 5311068

Tramadol

Approved, Investigational

Phase 4

27203-92-5

33741 5523

Ketamine

Approved, Vet_approved

Phase 4

6740-88-1, 1867-66-9

3821

Pregabalin

Approved, Investigational

Phase 4

148553-50-8

5486971

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Desflurane

Approved

Phase 4

57041-67-5

42113

Clonidine

Approved

Phase 4

4205-91-8, 4205-90-7

2803 20179

Droperidol

Approved, Vet_approved

Phase 4

548-73-2

3168

Scopolamine

Approved, Investigational

Phase 4

51-34-3

153311 3000322

Topotecan

Approved, Investigational

Phase 4

123948-87-8, 119413-54-6

60699 60700

Methotrexate

Approved

Phase 4

1959-05-2, 59-05-2

4112 126941

Vemurafenib

Approved

Phase 4

918504-65-1

42611257

Gefitinib

Approved, Investigational

Phase 4

184475-35-2

123631

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

3003 5743

Sufentanil

Approved, Investigational

Phase 4

56030-54-7

41693

Flurbiprofen

Approved, Investigational

Phase 4

5104-49-4

3394

Aspartic acid

Approved, Nutraceutical

Phase 4

56-84-8

5960

Creatine

Approved, Investigational, Nutraceutical

Phase 4

57-00-1

586

Rivoceranib

Investigational

Phase 4

811803-05-1

11315474

Flurbiprofen axetil

Investigational

Phase 4

91503-79-6

Neurotransmitter Agents

Phase 4

Psychotropic Drugs

Phase 4

Pharmaceutical Solutions

Phase 4

Hypnotics and Sedatives

Phase 4

Anesthetics

Phase 4

Phosphodiesterase Inhibitors

Phase 4

Endostar protein

Phase 4

Central Nervous System Stimulants

Phase 4

N-Methylaspartate

Phase 4

Anti-Anxiety Agents

Phase 4

Anesthetics, Intravenous

Phase 4

Anesthetics, General

Phase 4

GABA Modulators

Phase 4

Diphosphonates

Phase 4

bilirubin

Phase 4

635-65-4

5280352

Interventional clinical trials:

(show top 50) (show all 6077)

#	Name	Status	NCT ID	Phase	Drugs
1	Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride in in Combination With EC/EP	Unknown status	NCT03890055	Phase 4	Anlotinib Hydrochloride
2	Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study	Unknown status	NCT02348450	Phase 4	Irinotecan;Etoposide;Cisplatin
3	A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC)	Unknown status	NCT03799601	Phase 4	Anlotinib;Docetaxel;Carboplatin
4	Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer	Unknown status	NCT02031601	Phase 4	Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin)
5	A Multicenter, Randomized, Open-label, Parallel-group Study of Paclitaxel Liposome and Cisplatin Compared With Gemcitabine and Cisplatin as First-line Therapy in Advanced Squamous Non-Small-Cell Lung Cancer	Unknown status	NCT02996214	Phase 4	Paclitaxel Liposome;Gemcitabine;Cisplatin
6	Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open, One-arm Clinical Study	Unknown status	NCT03792503	Phase 4	Apatinib;Pemetrexed
7	A Phase Ⅳ,Open,Multicenter,Single Arm Study to Evaluate the Efficacy of the Combination Conmana With Thalidomide in Patients With NSCLC(Non-Small-Cell-Lung-Cancer)	Unknown status	NCT02778893	Phase 4	Conmana;Thalidomide
8	Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study	Unknown status	NCT02480634	Phase 4	Zoledronic acid
9	Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics	Unknown status	NCT03264794	Phase 4	Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial;Gefitinib tablets (Yi Ruisha），First medication;Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.
10	Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research	Unknown status	NCT02513355	Phase 4	Changchun marina;cisplatin;Taxol;parapl
11	A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)	Unknown status	NCT01028729	Phase 4	Endostar;Gemcitabine-Cisplatin chemotherapy
12	High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study	Unknown status	NCT02404675	Phase 4	icotinib
13	The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) )	Unknown status	NCT01211002	Phase 4	radiotherapy / EP combined with recombinant human endostatin
14	A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer	Unknown status	NCT02195453	Phase 4	Yangzhengxiaoji Capsule;Placebo Capsule
15	Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study	Unknown status	NCT02194556	Phase 4	Sequential and maintenance icotinib;Maintenance icotinib
16	A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases	Unknown status	NCT01926171	Phase 4	Icotinib plus WBRT
17	Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study	Unknown status	NCT02103257	Phase 4	Sequential Icotinib Plus Chemotherapy;Icotinib
18	An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation	Unknown status	NCT01646450	Phase 4	Icotinib
19	Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma	Unknown status	NCT01665417	Phase 4	Experimental;Chemotherapy
20	Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin	Unknown status	NCT01336192	Phase 4	Gemcitabine;Best supportive care
21	A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients	Completed	NCT00608868	Phase 4	Gefitinib
22	Safety Study of Nivolumab for Selected Advanced Malignancies in India	Completed	NCT03444766	Phase 4	Nivolumab
23	ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study	Completed	NCT03550482	Phase 4
24	Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer	Completed	NCT00451906	Phase 4	Platinum-based chemotherapy;Bevacizumab [Avastin]
25	A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy	Completed	NCT00770588	Phase 4	Gefitinib;Placebo
26	Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis	Completed	NCT00762346	Phase 4	zometa
27	Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer	Completed	NCT03092986	Phase 4	Paclitaxel;Carboplatin;Cisplatin;Vinblastine Sulfate
28	A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Osimertinib in Indian Adult Patients With Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC).	Completed	NCT03853551	Phase 4	Osimertinib
29	A Phase III/IV, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (TAIL)	Completed	NCT03285763	Phase 4	Atezolizumab
30	A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates	Completed	NCT00765687	Phase 4	bisphosphates
31	Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer	Completed	NCT00686322	Phase 4	Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
32	Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy	Completed	NCT00380718	Phase 4	pemetrexed
33	A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis	Completed	NCT00099541	Phase 4	zoledronic acid
34	An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa	Completed	NCT01000740	Phase 4
35	A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer	Completed	NCT01066884	Phase 4	erlotinib [Tarceva]
36	Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response	Completed	NCT03655834	Phase 4	Pemetrexed
37	An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer	Completed	NCT00949910	Phase 4	Erlotinib
38	Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer	Completed	NCT00883675	Phase 4	Docetaxel-Carboplatin
39	A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations	Completed	NCT02514174	Phase 4	Afatinib
40	Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer	Completed	NCT02497118	Phase 4	Endostatin;Vinorelbine;Cisplatin
41	Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer	Completed	NCT01020786	Phase 4	Pemetrexed;Carboplatin
42	A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy	Completed	NCT01230710	Phase 4	Erlotinib
43	A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan	Completed	NCT01196078	Phase 4	erlotinib [Tarceva];vinorelbine
44	SINGLE-ARM STUDY TO EVALUATE THE SAFETY OF LORLATINIB IN ALK INHIBITOR-TREATED UNRESECTABLE ADVANCED AND/OR RECURRENT ALK-POSITIVE NON-SMALL CELL LUNG CANCER PARTICIPANTS IN INDIA	Completed	NCT04541706	Phase 4	Lorlatinib
45	A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor	Completed	NCT01287754	Phase 4	erlotinib [Tarceva]
46	A Phase 3b/4 Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer	Completed	NCT02869789	Phase 4	Nivolumab in combination with Ipilimumab
47	An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Completed	NCT01203917	Phase 4	Gefitinib
48	Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)	Completed	NCT02151149	Phase 4	nab-paclitaxel;Carboplatin
49	An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy	Completed	NCT02208843	Phase 4	Afatinib
50	Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy	Completed	NCT01442909	Phase 4	Docetaxel and pemetrexed

Search NIH Clinical Center for Small Cell Cancer of the Lung

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Cisplatin

CISPLATIN PWDR

Teniposide

Topotecan

Topotecan Hydrochloride

Cochrane evidence based reviews: small cell lung carcinoma

Sources

Genetic Tests for Small Cell Cancer of the Lung

Genetic tests related to Small Cell Cancer of the Lung:

#	Genetic test	Affiliating Genes
1	Small Cell Lung Carcinoma ²⁸	RB1

Sources

Anatomical Context for Small Cell Cancer of the Lung

Organs/tissues related to Small Cell Cancer of the Lung:

FMA: Lung

MalaCards : Lung, Lymph Node, Brain, Prostate, Cervix, T Cells, Breast

Sources

Publications for Small Cell Cancer of the Lung

Articles related to Small Cell Cancer of the Lung:

(show top 50) (show all 43359)

#	Title	Authors	PMID	Year
1	Comprehensive genomic profiles of small cell lung cancer. ⁶² ⁵⁷	George J...Thomas RK	26168399	2015
2	Molecular profiling of small cell lung cancer in a Japanese cohort. ⁶² ⁵	Wakuda K...Yamamoto N	24657128	2014
3	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. ⁶² ⁵⁷	Peifer M...Thomas RK	22941188	2012
4	Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. ⁶² ⁵⁷	Rudin CM...Seshagiri S	22941189	2012
5	Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. ⁶² ⁵⁷	Watkins DN...Baylin SB	12629553	2003
6	Microsatellite alterations in plasma DNA of small cell lung cancer patients. ⁶² ⁵⁷	Chen XQ...Anker P	8782463	1996
7	An unusually proximal deletion on the short arm of chromosome 3 in a patient with small cell lung cancer. ⁶² ⁵⁷	Daly MC...Rabbitts PH	1672284	1991
8	Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers. ⁶² ⁵⁷	Leduc F...van den Berg A	2536219	1989
9	Localization of human ERBA2 to the 3p22----3p24.1 region of chromosome 3 and variable deletion in small cell lung cancer. ⁶² ⁵⁷	Drabkin H...Gerber M	2848257	1988
10	Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. ⁶² ⁵⁷	Kok K...Postmus PE	2825033	1987
11	Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. ⁶² ⁵⁷	Brauch H...Minna J	2821398	1987
12	Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. ⁶² ⁵⁷	Naylor SL...Sakaguchi AY	2821400	1987
13	Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p. ⁶² ⁵⁷	Graziano SL...Comis RL	3030544	1987
14	Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. ⁶² ⁵⁷	de Leij L...The TH	2998591	1985
15	A 3p deletion in small cell lung carcinoma. ⁶² ⁵⁷	Falor WH...Wegryn S	2982478	1985
16	Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin. ⁶² ⁵⁷	Ruff MR...Pert CB	6089338	1984
17	A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). ⁶² ⁵⁷	Whang-Peng J...Minna JD	6286098	1982
18	Human lung small-cell carcinoma contains bombesin. ⁶² ⁵⁷	Erisman MD...Lazarus LH	6285381	1982
19	Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). ⁶² ⁵⁷	Whang-Peng J...Minna JD	6274023	1982
20	Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. ⁶² ⁵⁷	Gazdar AF...Minna JD	6265067	1981
21	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
22	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
23	Definition of a tumor suppressor locus within human chromosome 3p21-p22. ⁵⁷	Killary AM...Naylor SL	1438292	1992
24	Three distinct regions involved in 3p deletion in human lung cancer. ⁵⁷	Hibi K...Takahashi T	1347916	1992
25	Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. ⁵	Yandell DW...Dryja TP	2594029	1989
26	Restriction fragment length polymorphism studies show consistent loss of chromosome 3p alleles in small cell lung cancer patients' tumors. ⁵⁷	Johnson BE...Naylor SL	2900253	1988
27	Molecular genetics of lung cancer. ⁵⁷	Birrer MJ...Minna JD	3289123	1988
28	Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. ⁵⁷	Yokota J...Sugimura T	2892196	1987
29	Loss of heterozygosity for a chromosome 3 sequence presumably at 3p21 in small cell lung cancer. ⁵⁷	Mooibroek H...Buys CH	2885082	1987
30	A unique cell-surface protein phenotype distinguishes human small-cell from non-small-cell lung cancer. ⁵⁷	Baylin SB...Shaper JH	6289311	1982
31	Neuron-specific enolase is produced by neuroendocrine tumours. ⁵⁷	Tapia FJ...Pearse AG	6111674	1981
32	Cytogenetic effects of cigarette smoke condensates in vitro and in vivo. ⁵⁷	Madle S...Obe G	7333590	1981
33	MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. ⁴⁶	Gao W...Shu Y	20508945	2011
34	Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells. ⁵³ ⁶²	Guo L...Sun Y	20206622	2010
35	INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. ⁵³ ⁶²	Chiappori AA...Gabrilovich DI	20420527	2010
36	ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. ⁵³ ⁶²	Skov BG...Mellemgaard A	20104194	2010
37	Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. ⁵³ ⁶²	Vaculova A...Zhivotovsky B	20416058	2010
38	Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth. ⁵³ ⁶²	Sommer P...Ray DW	20015838	2010
39	Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. ⁵³ ⁶²	Tahir SK...Anderson MG	20179162	2010
40	Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer. ⁵³ ⁶²	Guo L...Zhang F	20004564	2010
41	Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas. ⁵³ ⁶²	Nagashio R...Okayasu I	20398190	2010
42	Small cell carcinoma of the brain without extracranial involvement by serial CT, MRI and PET. ⁵³ ⁶²	Terada T	20224732	2010
43	Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. ⁵³ ⁶²	Sholl LM...Hornick JL	19661786	2010
44	Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. ⁵³ ⁶²	Chang MH...Ahn MJ	20078550	2009
45	The diagnostic and prognostic value of ProGRP in lung cancer. ⁵³ ⁶²	Nisman B...Peretz T	20032442	2009
46	Flow cytometric detection of small cell lung cancer cells with aberrant CD45 expression in micrometastatic bone marrow. ⁵³ ⁶²	Danbara M...Higashihara M	19674995	2009
47	Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. ⁵³ ⁶²	Bruzzese F...Budillon A	19887547	2009
48	Caveolin-1 is an important factor for the metastasis and proliferation of human small cell lung cancer NCI-H446 cell. ⁵³ ⁶²	Yeh D...Wang Q	19718715	2009
49	Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. ⁵³ ⁶²	Yamada T...Yano S	19856060	2009
50	Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. ⁵³ ⁶²	Yazawa T...Kitamura H	19679880	2009

Sources

Genes for Small Cell Cancer of the Lung

Genes related to Small Cell Cancer of the Lung (5 elite genes):

(show all 47)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	RB1	RB Transcriptional Corepressor 1	Protein Coding	882.06	Pathogenic ⁵ Causative somatic mutation ⁵⁸ Genetic Tests ²⁸ Likely pathogenic ⁵ Novoseek inferred ⁵³	2594029 25157968 26168399 (more) 15223960 8058306 1329054 2181449 7936665 11832187 8809405 20082263 10649246 11832104 9192669 12612881 7834618 1844252 10910097 2167152 12441277 1862090 16613540 8289506 8960146 11030152
2	TP53	Tumor Protein P53	Protein Coding	387.24	Causative somatic mutation ⁵⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	26168399 26619011 10582680 (more) 16158936 1648702 8103676 9713494 18547617 7904273 14652820 15223960 10656731 10200459 16328005 1935458 1322237 8100413 2175605 12692194 14660794 7889499 7615696 8733762 9857649 12657131 15863268 16211279 11641789 11812373 8731828 7833367 8078807 1312896 17932356 17264600 11716177 1364172 20206622 20004564 19276245 16990721 10029452 20420527 18656241 18580310 16386221 16479062 12490120 9721711 9614375 9120721 8887616 8082221 14618621 11557115 10452502 7590488 7546652 8639050 20224732 16080190 8934544 8635391 1310070 18510672 17966099 9885984 9589350 1346589 12478483 12441277 9615783 9815799 8809405 8519417 19531681 17091766 15735665 15551330 10212809 9849416 8794405 9618472
3	MIR21	MicroRNA 21	RNA Gene	350	Causal ⁴⁶	20508945
4	TP73	Tumor Protein P73	Protein Coding	350	Causative somatic mutation ⁵⁸	26168399
5	SCLC1	Small Cell Cancer Of The Lung	Genetic Locus	58.98	Genetic linkage ⁵⁷ GeneCards inferred via : Gene name (show sections)
6	HOTTIP	HOXA Distal Transcript Antisense RNA	RNA Gene	152.96	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	29367594
7	CCAT2	Colon Cancer Associated Transcript 2	RNA Gene	150	Experimental evidence: Regulation ³⁷	27470400
8	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	150	Experimental evidence: Regulation ³⁷	24591352 26707824
9	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	150	Experimental evidence: Expression ³⁷	22928560
10	TUG1	Taurine Up-Regulated 1	Protein Coding	150	Experimental evidence: Expression ³⁷	28069000
11	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	30.31	Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	26619011 17275257 18757405 (more) 10834940 15317667
12	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	28.25	Likely pathogenic ⁵ DISEASES inferred ¹⁴	25157968 24657128
13	PTEN	Phosphatase And Tensin Homolog	Protein Coding	27.95	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
13	PTEN::MIR21 ⁴⁶	MIR21 Macro RNA (hsa-miR-21) targets PTEN
14	B2M	Beta-2-Microglobulin	Protein Coding	25	Likely pathogenic ⁵	26619011
15	ENO2	Enolase 2	Protein Coding	17.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10460660 1684395 7915589 (more) 9176714 9805763 16159442 10622207 2158809 18404793 1703432 19031951 9337535 15274381 17618570 11791391 9506348 1803146 10433016 8386493 11299750 7657349 8658380 19047109 10188885 1702634 1965447 11956631 11008009 1965544 2160568 15624359 10699689 7474404 7987543 8323631 1444841 1663720 8983362 8630460 8287126 8385978 1324376 1645171 2300384 11930699 11288956 8110494 8272160 8380696 10470218 8111322 2167141 2162690 10690544 10081650 12928122 12581564 9337536 8630459 7589398 7523546 9253344 8938952 8869990 8230759 1766488 19024326 18516922 8111325 1657081 1654076 2164112 16793621 17913444 16325513 10996422 9815547 11041023 10425319 7890531 7507359 8431307 1333786 1325829 1753499 7687515 12820318 12168905 1723753 7602791 7629420 9082707
16	GRP	Gastrin Releasing Peptide	Protein Coding	16.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8262160 19031951 10470218 (more) 2169019 1325285 11391593 14660794 10413197 9228385 1693372 15382037 8732666 12009231 7784258 15234231 10433016 19047109 1702634 1668786 8174119 9468588 12820318 19149223 1320893 16609038 8044796 1671171 19856060 15809493 15365423 10355747 7962132 7690008 19642102 17390617 15148831 14581370 7559089 7832477 8241020 1337763 1563005 19824798 15498503 11791391 9622091 7551956 8132585 8391296 1329046 1565825 20032442 16490321 16277024 15274381 12733150 12639697 12581564 10545285 9927255 8664052 1663360 1851748 2166149 1752059 16039952 15751842 15350601 15192313 12820319 10771023 8691602 7809097 7809021 8134305 8280369 8095043 1314137 1717141 2083220 17906699 16633328 12570813 11762716 8581371 8100710 19124278 17874417 1688510 19133990 14698533 10915224 8806107 1400423 1331597
17	SYP	Synaptophysin	Protein Coding	16.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19321468 10460660 15816436 (more) 15899778 16159442 14533935 16937295 16896889 18726606 10987260 11557784 12478483 16325513 19674995 19844156 9331295 15132850 18516922 20224732 18463964 16648660 2168288 8639050 8869990 16734258 17046168 2165182
18	CHGA	Chromogranin A	Protein Coding	16.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10460660 16159442 11288956 (more) 1315401 1723753 9082707 10574253 14533935 8385978 10996422 19844156 11020854 8837344 2168288 10029452 9230910 2316306 8869990 1851827 15132850 16648660 12581564 19294493 10776528 18726606 9452263 1325178 15816436 15899778
19	NKX2-1	NK2 Homeobox 1	Protein Coding	14.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10757334 10976695 16084939 (more) 11175640 10728812 12499091 19578049 15309021 18227018 18626520 15471255 8814700 17727473 15098255 16862075 16625069 9064286 15084379 10665914 11533085 18587322 9950155 11668468 15381902 19390995 17885493 17062341 18091383 11257635 17951193 12760288 12379752 11956814 12923324 20224732 18091384 10792482 19661786 15257545 18071837 15494931
20	NCAM1	Neural Cell Adhesion Molecule 1	Protein Coding	13.89	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16159442 9416693 2165922 (more) 1314069 8391379 17949897 1719260 1337798 7513253 16648660 10850459 15926079 9824008 8794404 18726606 9777989 7936364 8213222
21	KRT20	Keratin 20	Protein Coding	12.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11175640 9042291 10728812 (more) 19321468 10976695 16084939 11533085 16625069 15166668 10937047 16538063 15494931 11668468
22	ASCL1	Achaete-Scute Family BHLH Transcription Factor 1	Protein Coding	12.43	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18587322 11948117 9144241 (more) 11193209 18421308
23	POMC	Proopiomelanocortin	Protein Coding	12.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18322802 7935088 8388056 (more) 8800643 8954027 8314205 1314126 1325994 8383976 7857271 8111702 8639050 1967615 8163665 7962350
24	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	12.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15044919 7514077 18989797 (more) 19351368 15946380 15812822 12748309 12610357 7514496 16082245 17420067 16342249 12711118 16550970 10910097 1707753 20224732 16818499 12414661 16242000 15499612 17274819 14657715 16844734 18091382 16161057 17536302 8542594 9788619 11325836
25	SST	Somatostatin	Protein Coding	11.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1686316 1973071 7915618 (more) 17921711 18852217 1654981 7908199 8015359 1352126 7698538 7833144 8955339 15751842 7857271 8392488 7763254 8314205 8935599 15301877
26	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	11.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1652377 11791391 17618570 (more) 15363304 8272160
27	TOP1	DNA Topoisomerase I	Protein Coding	11.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17645849 8853931 15735665 (more) 19996589 8093110 12237920 19887547 11801571 15511212 8631015 15616149 15923621 18670309 16022921 16962784
28	RCVRN	Recoverin	Protein Coding	11.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15301870 11557119 10740224 (more) 10766180 17374419 15084384 8794409
29	KRT7	Keratin 7	Protein Coding	11.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19321468 15494931 11668468 (more) 20398190 10987260 16084939 20224732
30	EGFR	Epidermal Growth Factor Receptor	Protein Coding	10.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17289890 17784875 10770635 (more) 18829487 17601631 12910109 16552419 17536302 19240370 1317257 15875085 19149760 11774237 17875767 12711118 10963846 17237005 16564920 12938261 19889201 17913857 16705311 19275641 18720932 8391303 18705417 15492792 18757405 16488055 17947472 17671148
31	MYCL	MYCL Proto-Oncogene, BHLH Transcription Factor	Protein Coding	10.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1331597 9747881 19020549 (more) 2171744 2154327 1851085
32	CALCA	Calcitonin Related Polypeptide Alpha	Protein Coding	10.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8394229 11768719 8019984 (more) 8111580 10420227 11762716 1965544 1331173
33	INSM1	INSM Transcriptional Repressor 1	Protein Coding	10.19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8364910
34	GAST	Gastrin	Protein Coding	10.19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1327522 10541353 10452322 (more) 9553173 8804078 9575243 8221657
35	BCL2	BCL2 Apoptosis Regulator	Protein Coding	10.09	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16361157 8570134 12657131 (more) 10216499 7977636 8261463 16677475 9615758 9030234 18091382 8733762 12441277 12729794 10029452 9818030 15020613 12644466 10374782 8639050 8865121 15026553 20179162 18381439 16479062 12490120 9614375 8938949 8733771 20206622 20004564 16022909 9615783 19372561 12838300 10355747 9673391 18519752 10212809
36	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	9.81	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15223960 10339660 10547597 (more) 9731504 9012464 11832187 18794045 20082263 11812373 15455389 16862075 11832104 9484839 16990721 9388844 7551956 18580310 17581410 14506638 8838105 12692194 7882351 17727473 16633070 20164052
37	MYCN	MYCN Proto-Oncogene, BHLH Transcription Factor	Protein Coding	9.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8669886 12880971 15975048 (more) 1571096 2171744 2154327 8535284 9365831
38	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	9.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8123593 10984118 7654239 (more) 9626477 7689933 1655253 11768610 10074929 10646866 2154327 9460496 8353142 2171744 8390424 1330296 10523691
39	AVP	Arginine Vasopressin	Protein Coding	9.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	2153841 12479696 1656520
40	PTPRC	Protein Tyrosine Phosphatase Receptor Type C	Protein Coding	9.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17525641
41	ELAVL4	ELAV Like RNA Binding Protein 4	Protein Coding	8.93	Novoseek inferred ⁵³	11090964 9288629 14512168 (more) 8069866 9633765 9815574 9829748
42	KLK3	Kallikrein Related Peptidase 3	Protein Coding	8.79	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18162772 14629757 12163395 (more) 10389621 17230567 1717124 9008037 2249589
43	GRPR	Gastrin Releasing Peptide Receptor	Protein Coding	8.68	Novoseek inferred ⁵³	11062732 15809493 19016795 (more) 8581371 7832477 14581370 12009231 1851748 1655761 9406683 12474049
44	CKB	Creatine Kinase B	Protein Coding	8.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1645850 1645171 7657349 (more) 1766488
45	KRT18	Keratin 18	Protein Coding	8.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1374358 20224732
46	HTATIP2	HIV-1 Tat Interactive Protein 2	Protein Coding	8.04	Novoseek inferred ⁵³	19349353
47	NMB	Neuromedin B	Protein Coding	7.99	Novoseek inferred ⁵³	1671171 7832477

Sources

Variations for Small Cell Cancer of the Lung

ClinVar genetic disease variations for Small Cell Cancer of the Lung:

⁵ (show top 50) (show all 106)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	overlap with 54 genes	t(2;2)(p23;p21)(hg19 chr2:g.42552694::ochr2:g.29446394)	INVERS	Pathogenic	487484		GRCh37: 2:29446394-42552694 GRCh38:
2	RB1	NM_000321.3(RB1):c.2242G>T (p.Glu748Ter)	SNV	Pathogenic	13078	rs121913297	GRCh37: 13:49039164-49039164 GRCh38: 13:48465028-48465028
3	RB1	NM_000321.3(RB1):c.1215+1G>A	SNV	Pathogenic	126832	rs587776783	GRCh37: 13:48947629-48947629 GRCh38: 13:48373493-48373493
4	RB1	NM_000321.3(RB1):c.1981C>T (p.Arg661Trp)	SNV	Pathogenic	13087	rs137853294	GRCh37: 13:49033844-49033844 GRCh38: 13:48459708-48459708
5	TP53	NM_000546.6(TP53):c.857A>G (p.Glu286Gly)	SNV	Likely Pathogenic	376590	rs1057519985	GRCh37: 17:7577081-7577081 GRCh38: 17:7673763-7673763
6	TP53	NM_000546.6(TP53):c.746G>T (p.Arg249Met)	SNV	Likely Pathogenic	376653	rs587782329	GRCh37: 17:7577535-7577535 GRCh38: 17:7674217-7674217
7	TP53	NM_000546.6(TP53):c.577C>G (p.His193Asp)	SNV	Likely Pathogenic	376613	rs876658468	GRCh37: 17:7578272-7578272 GRCh38: 17:7674954-7674954
8	TP53	NM_000546.6(TP53):c.645T>G (p.Ser215Arg)	SNV	Likely Pathogenic	376661	rs1057520001	GRCh37: 17:7578204-7578204 GRCh38: 17:7674886-7674886
9	TP53	NM_000546.6(TP53):c.856G>C (p.Glu286Gln)	SNV	Likely Pathogenic	376591	rs786201059	GRCh37: 17:7577082-7577082 GRCh38: 17:7673764-7673764
10	TP53	NM_000546.6(TP53):c.731G>T (p.Gly244Val)	SNV	Likely Pathogenic	376601	rs985033810	GRCh37: 17:7577550-7577550 GRCh38: 17:7674232-7674232
11	TP53	NM_000546.6(TP53):c.820G>C (p.Val274Leu)	SNV	Likely Pathogenic	376678	rs1057520005	GRCh37: 17:7577118-7577118 GRCh38: 17:7673800-7673800
12	TP53	NM_000546.6(TP53):c.518T>C (p.Val173Ala)	SNV	Likely Pathogenic	376017	rs1057519747	GRCh37: 17:7578412-7578412 GRCh38: 17:7675094-7675094
13	TP53	NM_000546.6(TP53):c.644G>A (p.Ser215Asn)	SNV	Likely Pathogenic	376662	rs587782177	GRCh37: 17:7578205-7578205 GRCh38: 17:7674887-7674887
14	PTEN	NM_000314.8(PTEN):c.388C>G (p.Arg130Gly)	SNV	Likely Pathogenic	375958	rs121909224	GRCh37: 10:89692904-89692904 GRCh38: 10:87933147-87933147
15	PIK3CA	NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln)	SNV	Likely Pathogenic	376244	rs121913273	GRCh37: 3:178936082-178936082 GRCh38: 3:179218294-179218294
16	PIK3CA	NM_006218.4(PIK3CA):c.1625A>T (p.Glu542Val)	SNV	Likely Pathogenic	376474	rs1057519927	GRCh37: 3:178936083-178936083 GRCh38: 3:179218295-179218295
17	B2M	NM_004048.4(B2M):c.2T>G (p.Met1Arg)	SNV	Likely Pathogenic	376372	rs1057519879	GRCh37: 15:45003746-45003746 GRCh38: 15:44711548-44711548
18	PIK3CA	NM_006218.4(PIK3CA):c.1625A>G (p.Glu542Gly)	SNV	Likely Pathogenic	376475	rs1057519927	GRCh37: 3:178936083-178936083 GRCh38: 3:179218295-179218295
19	PIK3CA	NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)	SNV	Likely Pathogenic	375896	rs104886003	GRCh37: 3:178936091-178936091 GRCh38: 3:179218303-179218303
20	PIK3CA	NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly)	SNV	Likely Pathogenic	13656	rs121913274	GRCh37: 3:178936092-178936092 GRCh38: 3:179218304-179218304
21	B2M	NM_004048.4(B2M):c.3G>A (p.Met1Ile)	SNV	Likely Pathogenic	376368	rs1057519877	GRCh37: 15:45003747-45003747 GRCh38: 15:44711549-44711549
22	B2M	NM_004048.4(B2M):c.1A>G (p.Met1Val)	SNV	Likely Pathogenic	376369	rs1023835002	GRCh37: 15:45003745-45003745 GRCh38: 15:44711547-44711547
23	PIK3CA	NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)	SNV	Likely Pathogenic	13655	rs104886003	GRCh37: 3:178936091-178936091 GRCh38: 3:179218303-179218303
24	TP53	NM_000546.6(TP53):c.517G>A (p.Val173Met)	SNV	Likely Pathogenic	233951	rs876660754	GRCh37: 17:7578413-7578413 GRCh38: 17:7675095-7675095
25	TP53	NM_000546.6(TP53):c.746G>A (p.Arg249Lys)	SNV	Likely Pathogenic	142241	rs587782329	GRCh37: 17:7577535-7577535 GRCh38: 17:7674217-7674217
26	TP53	NM_000546.6(TP53):c.818G>C (p.Arg273Pro)	SNV	Likely Pathogenic	231060	rs28934576	GRCh37: 17:7577120-7577120 GRCh38: 17:7673802-7673802
27	TP53	NM_000546.6(TP53):c.745A>G (p.Arg249Gly)	SNV	Likely Pathogenic	376654	rs587782082	GRCh37: 17:7577536-7577536 GRCh38: 17:7674218-7674218
28	TP53	NM_000546.6(TP53):c.731G>A (p.Gly244Asp)	SNV	Likely Pathogenic	372785	rs985033810	GRCh37: 17:7577550-7577550 GRCh38: 17:7674232-7674232
29	TP53	NM_000546.6(TP53):c.742C>T (p.Arg248Trp)	SNV	Likely Pathogenic	12347	rs121912651	GRCh37: 17:7577539-7577539 GRCh38: 17:7674221-7674221
30	TP53	NM_000546.6(TP53):c.587G>C (p.Arg196Pro)	SNV	Likely Pathogenic	231165	rs483352697	GRCh37: 17:7578262-7578262 GRCh38: 17:7674944-7674944
31	TP53	NM_000546.6(TP53):c.838A>G (p.Arg280Gly)	SNV	Likely Pathogenic	376658	rs753660142	GRCh37: 17:7577100-7577100 GRCh38: 17:7673782-7673782
32	TP53	NM_000546.6(TP53):c.643A>G (p.Ser215Gly)	SNV	Likely Pathogenic	265337	rs886039484	GRCh37: 17:7578206-7578206 GRCh38: 17:7674888-7674888
33	TP53	NM_000546.6(TP53):c.839G>C (p.Arg280Thr)	SNV	Likely Pathogenic	12368	rs121912660	GRCh37: 17:7577099-7577099 GRCh38: 17:7673781-7673781
34	TP53	NM_000546.6(TP53):c.857A>C (p.Glu286Ala)	SNV	Likely Pathogenic	376593	rs1057519985	GRCh37: 17:7577081-7577081 GRCh38: 17:7673763-7673763
35	TP53	NM_000546.6(TP53):c.730G>C (p.Gly244Arg)	SNV	Likely Pathogenic	376602	rs1057519989	GRCh37: 17:7577551-7577551 GRCh38: 17:7674233-7674233
36	TP53	NM_000546.6(TP53):c.857A>T (p.Glu286Val)	SNV	Likely Pathogenic	376592	rs1057519985	GRCh37: 17:7577081-7577081 GRCh38: 17:7673763-7673763
37	TP53	NM_000546.6(TP53):c.374C>A (p.Thr125Lys)	SNV	Likely Pathogenic	216465	rs786201057	GRCh37: 17:7579313-7579313 GRCh38: 17:7675995-7675995
38	TP53	NM_000546.6(TP53):c.659A>C (p.Tyr220Ser)	SNV	Likely Pathogenic	12383	rs121912666	GRCh37: 17:7578190-7578190 GRCh38: 17:7674872-7674872
39	TP53	NM_000546.6(TP53):c.373A>C (p.Thr125Pro)	SNV	Likely Pathogenic	376666	rs1057520003	GRCh37: 17:7579314-7579314 GRCh38: 17:7675996-7675996
40	TP53	NM_000546.6(TP53):c.658T>G (p.Tyr220Asp)	SNV	Likely Pathogenic	376689	rs530941076	GRCh37: 17:7578191-7578191 GRCh38: 17:7674873-7674873
41	TP53	NM_000546.6(TP53):c.577C>A (p.His193Asn)	SNV	Likely Pathogenic	376614	rs876658468	GRCh37: 17:7578272-7578272 GRCh38: 17:7674954-7674954
42	TP53	NM_000546.6(TP53):c.839G>T (p.Arg280Ile)	SNV	Likely Pathogenic	161517	rs121912660	GRCh37: 17:7577099-7577099 GRCh38: 17:7673781-7673781
43	TP53	NM_000546.6(TP53):c.821T>A (p.Val274Asp)	SNV	Likely Pathogenic	376675	rs1057520006	GRCh37: 17:7577117-7577117 GRCh38: 17:7673799-7673799
44	TP53	NM_000546.6(TP53):c.518T>G (p.Val173Gly)	SNV	Likely Pathogenic	376016	rs1057519747	GRCh37: 17:7578412-7578412 GRCh38: 17:7675094-7675094
45	RB1	NM_000321.3(RB1):c.2117G>T (p.Cys706Phe)	SNV	Likely Pathogenic	376330	rs121913295	GRCh37: 13:49037877-49037877 GRCh38: 13:48463741-48463741
46	PIK3CA	NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp)	SNV	Likely Pathogenic	217293	rs121913275	GRCh37: 3:178936093-178936093 GRCh38: 3:179218305-179218305
47	B2M	NM_004048.4(B2M):c.1A>T (p.Met1Leu)	SNV	Likely Pathogenic	376370	rs1023835002	GRCh37: 15:45003745-45003745 GRCh38: 15:44711547-44711547
48	B2M	NM_004048.4(B2M):c.2T>C (p.Met1Thr)	SNV	Likely Pathogenic	376371	rs1057519879	GRCh37: 15:45003746-45003746 GRCh38: 15:44711548-44711548
49	AKT1	NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys)	SNV	Likely Pathogenic	13983	rs121434592	GRCh37: 14:105246551-105246551 GRCh38: 14:104780214-104780214
50	PIK3CA	NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala)	SNV	Likely Pathogenic	376473	rs1057519927	GRCh37: 3:178936083-178936083 GRCh38: 3:179218295-179218295

Copy number variations for Small Cell Cancer of the Lung from CNVD:

⁶ (show top 50) (show all 515)

#	CNVD ID	Chromosome	Start	End	Type	CNVD Disease
1	15909	1	120235683	147296355	Substitutions and indels	small cell lung cancer
2	18774	1	147306435	159745095	Substitutions and indels	small cell lung cancer
3	21590	1	159753915	159864147	Substitutions and indels	small cell lung cancer
4	21631	1	159879159	167481135	Substitutions and indels	small cell lung cancer
5	22562	1	167488767	167515635	Substitutions and indels	small cell lung cancer
6	22575	1	167524383	182844003	Substitutions and indels	small cell lung cancer
7	22643	1	16801095	16840107	Substitutions and indels	small cell lung cancer
8	22724	1	16861959	29150031	Substitutions and indels	small cell lung cancer
9	24621	1	182849019	182888703	Substitutions and indels	small cell lung cancer
10	24623	1	182893695	194979795	Substitutions and indels	small cell lung cancer
11	25853	1	194993223	195074031	Substitutions and indels	small cell lung cancer
12	25942	1	195088143	205083387	Substitutions and indels	small cell lung cancer
13	27160	1	205088907	205109547	Substitutions and indels	small cell lung cancer
14	27163	1	205114395	208124379	Substitutions and indels	small cell lung cancer
15	27411	1	208129227	208155879	Substitutions and indels	small cell lung cancer
16	27424	1	208162923	222138663	Substitutions and indels	small cell lung cancer
17	28412	1	222150063	222281979	Substitutions and indels	small cell lung cancer
18	28435	1	222297471	247249719	Substitutions and indels	small cell lung cancer
19	31650	1	29155527	30043083	Substitutions and indels	small cell lung cancer
20	31718	1	30048807	41173191	Substitutions and indels	small cell lung cancer
21	32828	1	39746	16783059	Substitutions and indels	small cell lung cancer
22	33011	1	41174800	41175800	Intrachromosomal rearrangement	small cell lung cancer
23	33013	1	41178543	42371163	Substitutions and indels	small cell lung cancer
24	33099	1	42374208	42375208	Intrachromosomal rearrangement	small cell lung cancer
25	33100	1	42376011	42579327	Substitutions and indels	small cell lung cancer
26	33116	1	42583395	42584395	Intrachromosomal rearrangement	small cell lung cancer
27	33117	1	42584427	44255643	Substitutions and indels	small cell lung cancer
28	33294	1	44259752	44260752	Intrachromosomal rearrangement	small cell lung cancer
29	33295	1	44260511	44261511	Intrachromosomal rearrangement	small cell lung cancer
30	33296	1	44260527	44275323	Substitutions and indels	small cell lung cancer
31	33300	1	44279330	44280330	Intrachromosomal rearrangement	small cell lung cancer
32	33301	1	44279742	44280742	Intrachromosomal rearrangement	small cell lung cancer
33	33302	1	44280303	48578211	Substitutions and indels	small cell lung cancer
34	33819	1	48580747	48581747	Intrachromosomal rearrangement	small cell lung cancer
35	33821	1	48583227	51275739	Substitutions and indels	small cell lung cancer
36	33980	1	51279608	51280608	Intrachromosomal rearrangement	small cell lung cancer
37	33981	1	51281079	54467547	Substitutions and indels	small cell lung cancer
38	34296	1	54469360	54470360	Intrachromosomal rearrangement	small cell lung cancer
39	34297	1	54473247	54557103	Substitutions and indels	small cell lung cancer
40	34301	1	54561497	54562497	Intrachromosomal rearrangement	small cell lung cancer
41	34302	1	54562083	54649251	Substitutions and indels	small cell lung cancer
42	34322	1	54652634	54653634	Intrachromosomal rearrangement	small cell lung cancer
43	34323	1	54654159	57627915	Substitutions and indels	small cell lung cancer
44	34908	1	57632775	57657135	Substitutions and indels	small cell lung cancer
45	34910	1	57661947	72536187	Substitutions and indels	small cell lung cancer
46	36221	1	72541191	72583059	Substitutions and indels	small cell lung cancer
47	36257	1	72587919	85749039	Substitutions and indels	small cell lung cancer
48	37122	1	85755495	85774959	Substitutions and indels	small cell lung cancer
49	37129	1	85779879	120230763	Substitutions and indels	small cell lung cancer
50	41421	10	17866791	18173655	Substitutions and indels	small cell lung cancer

Sources

Expression for Small Cell Cancer of the Lung

Search GEO for disease gene expression data for Small Cell Cancer of the Lung.

Sources

Pathways for Small Cell Cancer of the Lung

Pathways related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

(show all 31)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.61	TP53 RB1 PTEN PIK3CA AKT1
2	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.37	TP53 PTEN PIK3CA AKT1
3	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.23	TP53 RB1 PTEN PIK3CA AKT1
4	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.16	TP53 PTEN PIK3CA AKT1
5	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.09	TP53 RB1 PTEN AKT1
6	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.04	TP53 RB1 PTEN PIK3CA AKT1
7	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.02	TP53 PTEN PIK3CA AKT1
8	Integrated breast cancer pathway ⁷⁴	12	AKT1 PTEN RB1 TP53
9	GDNF signaling ⁷⁴	11.93	SYP PTEN NCAM1 AKT1
10	Direct p53 effectors ⁶¹	11.9	TP73 TP53 RB1 PTEN
11	PI3K / Akt Signaling ³	11.79	PTEN PIK3CA AKT1
12	TP53 Regulates Metabolic Genes ⁶⁶	11.75	TP53 PTEN AKT1
13	Clear cell renal cell carcinoma pathways ⁷⁴	11.74	PTEN ENO2 AKT1
14	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.7	TP53 PIK3CA AKT1
15	DNA damage response (only ATM dependent) ⁷⁴	11.68	TP73 TP53 PTEN PIK3CA
16	p75(NTR)-mediated signaling ⁶¹ Show member pathways Ceramide signalling ⁶⁶ NFG and proNGF binds to p75NTR ⁶⁶	11.61	TP53 PIK3CA AKT1
17	BCR signaling pathway ⁶¹	11.59	PTEN PIK3CA AKT1
18	Thyroid stimulating hormone (TSH) signaling pathway ⁷⁴	11.54	AKT1 PIK3CA RB1
19	FGF signaling pathway ⁶¹	11.48	PIK3CA NCAM1 AKT1
20	Netrin-UNC5B signaling pathway ⁷⁴	11.46	TP53 PIK3CA AKT1
21	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.42	TP53 PTEN PIK3CA AKT1
22	Microtubule cytoskeleton regulation ⁷⁴	11.39	PTEN PIK3CA AKT1
23	Small cell lung cancer ⁷⁴	11.34	TP53 RB1 PTEN PIK3CA AKT1
24	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.32	TP53 PTEN PIK3CA AKT1
25	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities ⁷⁴	11.13	PTEN PIK3CA AKT1
26	Class I PI3K signaling events ⁶¹	11.07	PTEN PIK3CA AKT1
27	Integrated cancer pathway ⁷⁴	11.04	TP53 RB1 PTEN AKT1
28	Head and neck squamous cell carcinoma ⁷⁴	10.88	TP53 RB1 PTEN PIK3CA AKT1
29	Resolvin E1 and resolvin D1 signaling pathways promoting inflammation resolution ⁷⁴	10.73	PIK3CA AKT1
30	Caloric restriction and aging ⁷⁴	10.58	TP53 AKT1
31	Glycolysis in senescence ⁷⁴	10.52	TP53 RB1

Sources

GO Terms for Small Cell Cancer of the Lung

Biological processes related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.92	TP53 RB1 PIK3CA MIR21 AKT1
2	phosphatidylinositol 3-kinase signaling	GO:0014065	9.73	PTEN PIK3CA AKT1
3	positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway	GO:1900738	9.46	GRP CHGA
4	cellular response to decreased oxygen levels	GO:0036294	9.13	PTEN AKT1
5	negative regulation of mitotic cell cycle	GO:0045930	8.8	TP53 RB1 MIR21